InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

4D Molecular Therapeutics, Inc.

FDMT Clue Score62
United States Fiscal year ends December CIK 0001650648
$13.33 +4.96% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $13.33 −48.75% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 11 Dec 2020. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2019Revenue7.0Operating income−50.8Net income−49.3Fiscal year 2020Revenue13.4 +92.0%Operating income−56.7Net income−56.7Fiscal year 2021Revenue18.0 +35.0%Operating income−71.3Net income−71.3EPS, diluted−2.57Fiscal year 2022Revenue3.1 −82.7%Operating income−110.0Net income−107.5EPS, diluted−3.32Fiscal year 2023Revenue20.7 +562.3%Operating income−112.9Net income−100.8EPS, diluted−2.58Fiscal year 2024Revenue0.0 −99.8%Operating income−187.8Net income−160.9EPS, diluted−2.98Fiscal year 2025Revenue85.2 +230,194.6%Operating income−159.5Net income−140.1EPS, diluted−2.42
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 7.0 13.4 18.0 3.1 20.7 0.0 85.2
Growth +92.0% +35.0% −82.7% +562.3% −99.8% +230,194.6%
Operating income −50.8 −56.7 −71.3 −110.0 −112.9 −187.8 −159.5
Net income −49.3 −56.7 −71.3 −107.5 −100.8 −160.9 −140.1
Growth
EPS, diluted n/a n/a −2.57 −3.32 −2.58 −2.98 −2.42
Growth

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2019Operating margin−729.4%Net margin−708.4%Free cash flow margin−573.5%Fiscal year 2020Operating margin−424.0%Net margin−424.3%Free cash flow margin−388.5%Fiscal year 2021Operating margin−395.5%Net margin−395.4%Free cash flow margin−433.8%Fiscal year 2022Operating margin−3,516.5%Net margin−3,435.4%Free cash flow margin−3,139.1%Fiscal year 2023Operating margin−544.6%Net margin−486.6%Free cash flow margin−379.1%Fiscal year 2024Operating margin−507,678.4%Net margin−434,778.4%Free cash flow margin−373,975.7%Fiscal year 2025Operating margin−187.2%Net margin−164.4%Free cash flow margin−128.6%
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin −729.4% −424.0% −395.5% −3,516.5% −544.6% −507,678.4% −187.2%
Net margin −708.4% −424.3% −395.4% −3,435.4% −486.6% −434,778.4% −164.4%
Free cash flow margin −573.5% −388.5% −433.8% −3,139.1% −379.1% −373,975.7% −128.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2019Operating cash flow−36.7Capital expenditure−3.2Free cash flow−39.9Fiscal year 2020Operating cash flow−50.9Capital expenditure−1.0Free cash flow−51.9Fiscal year 2021Operating cash flow−69.1Capital expenditure−9.1Free cash flow−78.2Fiscal year 2022Operating cash flow−86.7Capital expenditure−11.5Free cash flow−98.2Fiscal year 2023Operating cash flow−75.8Capital expenditure−2.8Free cash flow−78.6Fiscal year 2024Operating cash flow−134.6Capital expenditure−3.8Free cash flow−138.4Fiscal year 2025Operating cash flow−109.1Capital expenditure−0.5Free cash flow−109.6
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −36.7 −50.9 −69.1 −86.7 −75.8 −134.6 −109.1
Capital expenditure −3.2 −1.0 −9.1 −11.5 −2.8 −3.8 −0.5
Free cash flow −39.9 −51.9 −78.2 −98.2 −78.6 −138.4 −109.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
CashTotal debt
Fiscal year 2019Cash49.7Shareholders’ equity−73.0Fiscal year 2020Cash276.7Shareholders’ equity256.4Fiscal year 2021Cash153.0Shareholders’ equity319.1Fiscal year 2022Cash52.4Shareholders’ equity231.3Fiscal year 2023Cash249.1Shareholders’ equity307.8Fiscal year 2024Cash149.3Shareholders’ equity510.6Fiscal year 2025Cash60.2Total debt0.0Net cash (debt)60.2Shareholders’ equity505.7Debt to equity0.00
FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 49.7 276.7 153.0 52.4 249.1 149.3 60.2
Total debt n/a n/a n/a n/a n/a n/a 0.0
Net cash (debt) n/a n/a n/a n/a n/a n/a 60.2
Shareholders’ equity −73.0 256.4 319.1 231.3 307.8 510.6 505.7
Debt to equity n/a n/a n/a n/a n/a n/a 0.00

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
7.0 13.4 18.0 3.1 20.7 0.0 85.2
Growth +92.0% +35.0% −82.7% +562.3% −99.8% +230,194.6%
13.9 17.2 28.0 32.9 36.5 46.6 49.1
−50.8 −56.7 −71.3 −110.0 −112.9 −187.8 −159.5
Growth
n/a 0.0 0.0 0.0 0.0 0.0 0.0
−49.3 −56.7 −71.3 −107.5 −100.8 −160.9 −140.1
Growth
Per share
n/a n/a −2.57 −3.32 −2.58 −2.98 −2.42
n/a n/a −2.57 −3.32 −2.58 −2.98 −2.42
Growth
n/a n/a 27.7 32.4 39.1 53.9 57.9
n/a n/a 27.7 32.4 39.1 53.9 57.9
Growth +16.7% +21.0% +37.9% +7.4%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 44.8% a year over five years.
  • Operating margin is up 236.8 points on five years ago, at -187.2%.
  • A net loss in 7 of 7 years on file.